Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 6, 2008, Pages 1062-1073

  Till, Brian G ^a,b   Gooley, Theodore A ^a,b   Crawford, Nathan ^a   Gopal, Ajay K ^a,b   Maloney, David G ^a,b   Petersdorf, Stephen H ^a,b   Pagel, John M ^a,b   Holmberg, Leona ^a,b   Bensinger, William ^a,b   Press, Oliver W ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autologous stem cell transplantation; CHOP; HyperCVAD; Mantle cell lymphoma; Non Hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE PROTEIN BCL 2 INHIBITOR; BUSULFAN; CARMUSTINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; PREDNISONE; PROTEIN INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 46749097256     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801923725     Document Type: Article

References (33)

1. Armitage, J. O. and Weisenburger, D. D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol, 16, pp. 2780-2795.
2. Bosch, F., Lopez-Guillermo, A., Campo, E., Ribera, J. M., Conde, E. Piris, M. A. et al. (1998) Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer, 82, pp. 567-575.
3. Oinonen, R., Franssila, K., Teerenhovi, L., Lappalainen, K. and Elonen, E. (1998) Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients. Eur J Cancer, 34, pp. 329-336.
4. Freedman, A. S., Neuberg, D., Gribben, J. G., Mauch, P., Soiffer, R. J. Fisher, D. C. et al. (1998) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol, 16, pp. 13-18.
5. Vose, J. M., Bierman, P. J., Weisenburger, D. D., Lynch, J. C., Bociek, Y. Chan, W. C. et al. (2000) Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant, 6, pp. 640-645.
6. Khouri, I. F., Saliba, R. M., Okoroji, G. J., Acholonu, S. A. and Champlin, R. E. (2003) Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: The prognostic value of beta2-microglobulin and the tumor score. Cancer, 98, pp. 2630-2635.
7. Lefrere, F., Delmer, A., Levy, V., Delarue, R., Varet, B. and Hermine, O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica, 89, pp. 1275-1276.
8. Mangel, J., Leitch, H. A., Connors, J. M., Buckstein, R., Imrie, K. Spaner, D. et al. (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol, 15, pp. 283-290.
9. Oinonen, R., Jantunen, E., Itala, M., Lehtinen, T., Kuittinen, O. Franssila, K. et al. (2002) Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymphoma, 43, pp. 1229-1237.
10. Ritchie, D. S., Seymour, J. F., Grigg, A. P., Roberts, A. W., Hoyt, R. Thompson, S. et al. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol, 86, pp. 101-105.
11. Vigouroux, S., Gaillard, F., Moreau, P., Harousseau, J. L. and Milpied, N. (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica, 90, pp. 1580-1582.
12. Vandenberghe, E., Ruiz de Elvira, C, Loberiza, F. R., Conde, E., Lopez-Guillermo, A. Gisselbrecht, C. et al. (2003) Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol, 120, pp. 793-800.
13. Haas, R., Brittinger, G., Meusers, P., Murea, S., Goldschmidt, H. Wannenmacher, M. et al. (1996) Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia, 10, pp. 1975-1979.
14. de Guibert, S., Jaccard, A., Bernard, M., Turlure, P., Bordessoule, D. and Lamy, T. (2006) Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica, 91, pp. 425-426.
15. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C. Schmits, R. et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood, 105, pp. 2677-2684.
16. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U. Metzner, B. et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 23, pp. 1984-1992.
17. Nickenig, C., Dreyling, M., Hoster, E., Pfreundschuh, M., Trumper, L. Reiser, M. et al. (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer, 107, pp. 1014-1022.
18. Zucca, E., Roggero, E., Pinotti, G., Pedrinis, E., Cappella, C. Venco, A. et al. (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol, 6, pp. 257-262.
19. Zinzani, P. L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R. Zaccaria, A. et al. (2000) Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol, 18, pp. 773-779.
20. Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M., Poor, C. Janicek, M. J. et al. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol, 20, pp. 1288-1294.
21. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. Pro, B. et al. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
22. Conde, E., Marco, F., Caballero, D., Arranz, R., Lahuerta, J. J. Sureda, A. et al. (2002) Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL) [abstract]. Blood, 100, p. 2529a.
23. Vose, J., Loberiza, F. R., Bierman, P. J., Bociek, G. and Armitage, J. O. (2006) Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/ High dose methotrexate and cytarabine (M-C) (± rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol, 24, p. 7511a.
24. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon
25. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. Connors, J. M. et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, pp. 2454-2460.
26. Ketterer, N., Salles, G., Espinouse, D., Dumontet, C., Neidhardt-Berard, E. M. Moullet, I. et al. (1997) Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol, 8, pp. 701-704.
27. Dreger, P., Martin, S., Kuse, R., Sonnen, R., Glass, B. Kroger, N. et al. (2000) The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: A joint analysis of two prospective studies with 46 patients. Hematol J, 1, pp. 87-94.
28. Gianni, A. M., Magni, M., Martelli, M., Di Nicola, M, Carlo-Stella, C. Pilotti, S. et al. (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 102, pp. 749-755.
29. Kasamon, Y. L., Jones, R. J., Diehl, L. F., Nayer, H., Borowitz, M. J. Garrett-Mayer, E. et al. (2005) Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant, 11, pp. 39-46.
30. Ganti, A. K., Bierman, P. J., Lynch, J. C., Bociek, R. G., Vose, J. M. and Armitage, J. O. (2005) Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol, 16, pp. 618-624.
31. Andersen, N. S., Pedersen, L., Elonen, E., Johnson, A., Kolstad, A. Franssila, K. et al. (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: Outcome related to remission pretransplant. Eur J Haematol, 71, pp. 73-80.
32. Thieblemont, C., Antal, D., Lacotte-Thierry, L., Delwail, V., Espinouse, D. Michallet, A. S. et al. (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 104, pp. 1434-1441.
33. Gopal, A. K., Rajendran, J. G., Petersdorf, S. H., Maloney, D. G., Eary, J. F. Wood, B. L. et al. (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood, 99, pp. 3158-3162.